Woburn, MA, November 13, 2001
AlphaGene, Inc. of Woburn, MA, a functional genomics
company, announced it has entered into an agreement
with Celera Genomics to allow Celera to distribute
AlphaGene's extensive collection of human
full-length genes.
In order to capitalize on the growing demand within
the genomics research community for fully sequenced
full-length genes, AlphaGene and Celera Genomics
have entered into an agreement to provide these
clones to both academic and commercial researchers.
Celera will be responsible for marketing these
services through their Celera Discovery System (CDS)
subscription database. AlphaGene will be responsible
for isolating known clones found in public databases
through their AlphaGene Clone Database (ACD). Celera
will map the clone sequences to its proprietary
assembled human genome database. AlphaGene will
fully sequence and manufacture the clone, as well as
fulfill all orders generated by the CDS marketing
effort.
"This relationship is expected to enable Celera's
customers to access AlphaGene's comprehensive set of
full-length clones from well-characterized genes,"
said Jason Molle, general manager for Celera's
online business. "These cDNA reagents extend the CDS
information system as a critical tool for genomic
research."
AlphaGene's President and Chief Executive Officer,
Donald J. McCarren, Ph.D., noted that this
collaboration provides genomic researchers the
opportunity to access an exceptional full-length
physical gene inventory providing a platform to
facilitate functional genomics research and drug
discovery. Additionally, both AlphaGene and Celera
believe that this agreement will benefit both
companies in their quest to provide useful research
tools to customers.
About AlphaGene, Inc.
AlphaGene, Inc. (http://www.alphagene.com)
is a privately held functional genomics company
offering products and services to biotech and
pharmaceutical companies engaged in drug discovery and
development. AlphaGene uses its large inventory of
full-length cDNAs and Bioinformatics expertise to
bridge the gap between genomics and functional
proteomics. The company focuses on differential gene
expression in degenerative neurological diseases
including Parkinson's and Alzheimer's
Diseases.
About Celera Genomics
Celera Genomics (NYSE: CRA) is
one of the two trading stocks of Applera Corporation.
Applied Biosystems (NYSE: ABI) is the other,
and both are traded on the New York Stock Exchange.
The Celera Genomics Group, an integrated source of
genomic and related medical information headquartered
in Rockville, MD, is evolving to become a next
generation diagnostic and therapeutic discovery
company. Celera intends to leverage its industrialized
approach to biology to develop platforms for enabling
these new discoveries both for subscribers and for its
own internal product development.
